Usf Health

1. Novartis Pharmaceuticals Corporation $1,392,885 40 payments
2. Alexion Pharmaceuticals, Inc. $99,832 5 payments
3. W. L. Gore & Associates, Inc. $78,799 30 payments
4. TG Therapeutics, Inc. $75,425 7 payments
5. AstraZeneca UK Limited $26,050 1 payment
6. Molnlycke Health Care AB $19,558 2 payments
7. Ipsen Pharma SAS $17,962 10 payments
8. AngioDynamics, Inc. $16,800 6 payments
9. Pfizer Inc. $3,709 3 payments
10. Daiichi Sankyo Inc. $1,547 103 payments

1. A Randomized Subject and Investigator Blinded Placebo Controlled and Multi Center Platform Study to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa $364,208 3 payments
2. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $254,395 3 payments
3. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $204,945 3 payments
4. A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy $102,628 3 payments
5. A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-Term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa $98,336 4 payments
6. An open label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in pediatric patients with refractory generalized myasthenia gravis $84,141 2 payments
7. (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab $75,425 7 payments
8. A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy $51,261 2 payments
9. A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy $51,134 4 payments
10. A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light $37,648 1 payment

1. Other $14,500 5 payments
2. Patient care $2,300 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.